Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study-Reference-Cited by-同舟云学术

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

Published:2020-05-06 Issue:6 Volume:37 Page:2865-2883
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Kiltz Uta,Sfikakis Petros P.,Gaffney Karl,Sator Paul-Gunther,von Kiedrowski Ralph,Bounas Andreas,Gullick Nicola,Conrad Curdin,Rigopoulos Dimitris,Lespessailles Eric,Romanelli Marco,Ghislain Pierre-Dominique,Brandt-Jürgens Jan,Rashkov Rasho,Aassi Maher,Orsenigo Roberto,Perella Chiara,Pournara Effie,Gathmann Sven,Jagiello Piotr,Veit Justyna,Augustin Matthias

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-020-01352-8.pdf

Reference82 articles.

1. Schreiber S, Colombel J-F, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473–9.

2. Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.

3. Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007;56(4):1051–66.